• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Kamada Ltd. (Amendment)

    12/28/23 1:16:03 PM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KMDA alert in real time by email
    SC 13G/A 1 zk2330706.htm SC 13G/A


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549

    SCHEDULE 13G
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 15)*
     
    Kamada Ltd.
    (Name of Issuer)

    Ordinary Shares, par value NIS 1.00 each
     (Title of Class of Securities)

    M6240T109 
     (CUSIP Number)
     
    December 18, 2023
     (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. M6240T109
    13G
    Page 2 of 8 Pages

    1
    NAME OF REPORTING PERSONS
     
    The Phoenix Holdings Ltd.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP   (See instructions)
    (a)  ☐
    (b)  ☒
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
     
    ---
    6
    SHARED VOTING POWER
     
    4,314,268.12 (*)
    7
    SOLE DISPOSITIVE POWER
     
    ---
    8
    SHARED DISPOSITIVE POWER
     
    4,314,268.12 (*)
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    4,314,268.12 (*)
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)
     
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     
    7.51% (*)(**)
    12
    TYPE OF REPORTING PERSON   (See instructions)
     
    CO
     
    (*) The beneficial ownership of the securities reported herein is described in Item 4(a).

    (**) Based on 57,473,817 Ordinary Shares outstanding as of December 20, 2023 (as reported on Bloomberg LP).

    2

     

    Item 1. (a)               Name of Issuer:
     
    Kamada Ltd.

                 (b)
    Address of Issuer's Principal Executive Offices:

     2 Holtzman St., Science Park, P.O. Box 4081, Rehovot 7670402, Israel
     
    Item 2. (a)
    Name of Person Filing:

     
    The Phoenix Holdings Ltd.

    The securities reported herein are beneficially owned by various direct or indirect, majority or wholly-owned subsidiaries of the Phoenix Holdings Ltd. (the "Subsidiaries").  The Subsidiaries manage their own funds and/or the funds of others, including for holders of exchange-traded notes or various insurance policies, members of pension or provident funds, unit holders of mutual funds, and portfolio management clients.  Each of the Subsidiaries operates under independent management and makes its own independent voting and investment decisions.

     
    (b)
    Address of Principal Business Office:

    The address of the Phoenix Holdings Ltd. is Derech Hashalom 53, Givataim, 53454, Israel. 

     
    (c)
    Citizenship:

     
    The Phoenix Holdings Ltd. - Israel

     
    (d)
    Title of Class of Securities:
     
    Ordinary Shares, par value NIS 1.00 each

     
    (e)
    CUSIP Number:

    M6240T109
     
    3

     
    Item 3.
    Not applicable.

    Item 4.
    Ownership:

     
    (a)
    Amount beneficially owned:

     
    See row 9 of cover page of each reporting person.
     
     
    Each of the Subsidiaries operates under independent management and makes its own independent voting and investment decisions.  Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by either the Filing Persons or Subsidiaries that a group exists for purposes of Section 13(d) of the Securities Exchange Act of 1934 or for any other purpose, and each reporting person disclaims the existence of any such group.  In addition, each of the Filing Persons and Subsidiaries disclaims any beneficial ownership of the securities covered by this report in excess of their actual pecuniary interest therein. This Statement shall not be construed as an admission by the Filing Persons or Subsidiaries that they are the beneficial owners of any of the Ordinary Shares covered by this Statement.

               As of December 18, 2023, the securities reported herein were held as follows:

       
    Ordinary
    Shares
       
    Percentage of total
    Ordinary Shares
    outstanding
     
    The Phoenix Investments House -  "nostro" accounts
       
    --
         
    --
     
    The Phoenix Investments House - trust funds
       
    149,519
         
    0.26
    %
    The Phoenix Investments House -  ETF's
       
    --
         
    --
     
    The Phoenix "nostro" accounts
       
    --
         
    --
     
    The Phoenix pension and provident funds
       
    --
         
    --
     
    Linked insurance policies of Phoenix
       
    --
         
    --
     
    Partnership for Israeli shares (1)
       
    3,965,873
         
    6.90
    %
    Partnership for investing in shares indexes (1)
       
    198,876.12
         
    0.35
    %
    Partnership for international shares (1)
       
    --
         
    --
     
    Halman - Aldubi Provident and Pension Funds Ltd.
       
    --
         
    --
     

    (1) All ownership rights in this partnership belong to companies that are part of Phoenix Group. The amount of ownership rights held by such companies in the partnership changes frequently according to a mechanism provided in the partnership agreement

     
    (b)
    Percent of class:

     
    See row 11 of cover page of each reporting person

     
    4

     

     
    (c)
    Number of shares as to which such person has:

     
    (i)
    Sole power to vote or to direct the vote:
     
    See row 5 of cover page of each reporting person
     
     
    (ii)
    Shared power to vote or to direct the vote:
     
    See row 6 of cover page of each reporting person and note in Item 4(a) above
     
     
    (iii)
    Sole power to dispose or to direct the disposition of:
     
    See row 7 of cover page of each reporting person
     
     
    (iv)
    Shared power to dispose or to direct the disposition of:
     
    See row 8 of cover page of each reporting person and note in Item 4(a) above
     
    Item 5.
    Ownership of Five Percent or Less of a Class:

    Not applicable.

    Item 6.
    Ownership of More than Five Percent on Behalf of Another:

    Not applicable.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not applicable.

    Item 8.
    Identification and Classification of Members of the Group:

    Not applicable.

    Item 9.
    Notice of Dissolution of Group:

    Not applicable.
     
     
    5

     
     
    Item 10.
    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     
     6

     
    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    December 26, 2023
     
       
    The Phoenix Holdings Ltd.
     
    /s/ Eli Schwartz
    By: Eli Schwartz*
    Title: Executive Vice President - Chief Financial Officer

       
    /s/ Haggai Schreiber
    By: Haggai Schreiber*
    Title: Executive Vice President - Chief Investment Officer

    * Signature duly authorized by resolution of the Board of Directors, notice of which is attached as Exhibit 1 to this Schedule 13G.

    7

     
     
    EXHIBIT NO.
    DESCRIPTION
     
         
    Exhibit 1
    Notice of resolution of the Board of Directors of the Phoenix Holdings Ltd., dated as of December 12, 2019 (incorporated herein by reference to Exhibit 1 to the Schedule 13G filed on February 7, 2022).
     

    8


    Get the next $KMDA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KMDA

    DatePrice TargetRatingAnalyst
    3/21/2025$15.00Buy
    The Benchmark Company
    7/3/2024$18.00Buy
    Stifel
    More analyst ratings

    $KMDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Payorski Lilach

    3 - KAMADA LTD (0001567529) (Issuer)

    3/17/26 9:55:57 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Itshayek Assaf

    3 - KAMADA LTD (0001567529) (Issuer)

    3/16/26 10:35:59 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Gorelik Boris

    3 - KAMADA LTD (0001567529) (Issuer)

    3/16/26 7:10:44 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMDA
    SEC Filings

    View All

    SEC Form 6-K filed by Kamada Ltd.

    6-K - KAMADA LTD (0001567529) (Filer)

    3/17/26 4:00:15 PM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Kamada Ltd.

    SCHEDULE 13G/A - KAMADA LTD (0001567529) (Subject)

    3/16/26 9:53:53 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 20-F filed by Kamada Ltd.

    20-F - KAMADA LTD (0001567529) (Filer)

    3/11/26 7:24:34 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth

    2025 Full Year Revenue of $180.5 Million, up 12% Year-over-Year; Adjusted EBITDA of $42.0 Million, up 23% Year-over-Year; Net Income of $20.2 Million, up 40% Year-over-YearCompany Affirms 2026 Annual Guidance of $200 Million – $205 Million in Revenues and $50 Million – $53 Million of Adjusted EBITDA, Representing Double-Digit Organic GrowthGenerated $25.5 Million of Cash from Operations in 2025; as of December 31, 2025 had $75.5 Million of Available Cash Company Aims to Secure New Business Development and M&A Transactions to Accelerate Profitable GrowthCompany Adopted an Annual Cash Dividend Policy and Declares Cash Dividend of $0.25 Per Share (Totaling Approximately $14.4 Million)Conference

    3/11/26 7:02:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy

    REHOVOT, Israel and HOBOKEN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that its Board of Directors has declared a cash dividend of $0.25 (approximately NIS 0.77) per share on the Company's ordinary shares (totaling approximately $14.4 million). The cash dividend will be payable on April 6, 2026, to shareholders of record at the close of business on March 23, 2026. The dividend payment is made in accordance with the Company's annual cash dividend policy newly adopted b

    3/11/26 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026

    REHOVOT, Israel, and HOBOKEN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the fourth quarter and fiscal year that ended December 31, 2025, prior to the open of the U.S. financial markets on Wednesday, March 11, 2026. Kamada's management will host an investment community conference call on Wednesday, March 11, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may part

    3/4/26 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on Kamada with a new price target

    The Benchmark Company initiated coverage of Kamada with a rating of Buy and set a new price target of $15.00

    3/21/25 8:11:15 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Kamada with a new price target

    Stifel initiated coverage of Kamada with a rating of Buy and set a new price target of $18.00

    7/3/24 7:31:15 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMDA
    Financials

    Live finance-specific insights

    View All

    Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth

    2025 Full Year Revenue of $180.5 Million, up 12% Year-over-Year; Adjusted EBITDA of $42.0 Million, up 23% Year-over-Year; Net Income of $20.2 Million, up 40% Year-over-YearCompany Affirms 2026 Annual Guidance of $200 Million – $205 Million in Revenues and $50 Million – $53 Million of Adjusted EBITDA, Representing Double-Digit Organic GrowthGenerated $25.5 Million of Cash from Operations in 2025; as of December 31, 2025 had $75.5 Million of Available Cash Company Aims to Secure New Business Development and M&A Transactions to Accelerate Profitable GrowthCompany Adopted an Annual Cash Dividend Policy and Declares Cash Dividend of $0.25 Per Share (Totaling Approximately $14.4 Million)Conference

    3/11/26 7:02:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy

    REHOVOT, Israel and HOBOKEN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that its Board of Directors has declared a cash dividend of $0.25 (approximately NIS 0.77) per share on the Company's ordinary shares (totaling approximately $14.4 million). The cash dividend will be payable on April 6, 2026, to shareholders of record at the close of business on March 23, 2026. The dividend payment is made in accordance with the Company's annual cash dividend policy newly adopted b

    3/11/26 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026

    REHOVOT, Israel, and HOBOKEN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the fourth quarter and fiscal year that ended December 31, 2025, prior to the open of the U.S. financial markets on Wednesday, March 11, 2026. Kamada's management will host an investment community conference call on Wednesday, March 11, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may part

    3/4/26 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kamada Ltd.

    SC 13G/A - KAMADA LTD (0001567529) (Subject)

    11/14/24 6:21:51 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Kamada Ltd. (Amendment)

    SC 13G/A - KAMADA LTD (0001567529) (Subject)

    2/14/24 5:04:02 PM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Kamada Ltd. (Amendment)

    SC 13G/A - KAMADA LTD (0001567529) (Subject)

    2/12/24 12:41:57 PM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMDA
    Leadership Updates

    Live Leadership Updates

    View All

    Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds

    Funding Strengthens Kamada's Financial Position, Supporting its Growth Plans and the Pursuit of Strategic Business Development OpportunitiesAppointment of Two New Independent Directors to its Board: Professor Benjamin Dekel and Mr. Assaf Itshayek REHOVOT, Israel and HOBOKEN, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced shareholder approval and planned closing of the previously announced $60 million private placement (the "Private Placement") with FIMI Op

    8/30/23 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and Appointment of Nir Livneh as Vice President, General Counsel and Corporate Secretary

    REHOVOT, Israel and HOBOKEN, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))) ("Kamada" or the "Company"), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that following the recently announced $60 million private placement with the FIMI Opportunity Funds, which is expected to contribute to accelerating the growth of its existing business and allow the Company to pursue compelling business development opportunities, Chief Financial Officer (CFO), Chaime Orlev, who had previously planned to transition out of h

    5/24/23 7:05:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care